Genesis Healthcare launches its “Genesis Asia 1,000 Project”, decoding the whole genome of 1,000 Asians with rare diseases

SINGAPORE, Oct 31, 2018 — Genesis Healthcare Co., Japan’s pioneer genetic testing and research company, today announced the launch of “The Genesis Asia 1,000 Project”.


The aim of the project is to profile 1,000 whole genomes of Asian patients with rare diseases.


To kick-off this project Genesis Healthcare invites public participation of patients and researchers / research institutions from Japan, Singapore, Taiwan, Hong Kong, Indonesia, Malaysia, Thailand and Philippines.


In the absence of an existing genome database focusing on Asia, Genesis Healthcare will support researchers in Asia to identify causes of rare diseases and accelerate new drug discovery.


Genesis Healthcare will provide the whole genome sequencing for 1,000 patients free of cost and aim to cover the following diseases.

  • Alzheimer
  • Autism
  • Amyotrophic lateral sclerosis(ALS)
  • Myelopathic muscular atrophy
  • Parkinson’s disease
  • Multiple sclerosis/ Neuromyelitis optica
  • Moyamoya disease
  • Systemic lupus erythematosus(SLE)
  • Congenital myopathy
  • Tuberous sclerosis
  • And other rare diseases


Genesis Healthcare recently launched its New Sequencing Centerin Tokyo, Japan with the high-throughput Next Generation Sequencer (NGS) enabling high-quality whole genome sequencing of a large number of specimens at one time. Allowing to break the benchmarking price of 1,000 USD in Japan for the first time and extended to South East Asia for 99,800 JPY (889 USD) per specimen.


Available immediately, researchers can engage with Genesis Healthcare through its headquarters in Japan as well as regional offices in Singapore and Taiwan.


Genesis Healthcare is a leader in genetic research and testing with more than 650,000 users undertaking DNA testing across Asia.



Genesis Healthcare Co.
Corporate site:
Press inquiries: Yoshito Funabashi

Business inquiries: Ryo Itaya